Palantir Co-founder Had Explored Winning UK's NHS Via Buying Smaller Rivals: Report

Comments
Loading...
  • Palantir Technologies Inc PLTR harbored a secret plan to deepen its relationship with the U.K.'s National Health Service without public scrutiny.
  • Palantir aimed to buy up smaller rivals that already had an existing relationship with the NHS, Bloomberg reports citing relevant documents.
  • Palantir planned to take over small businesses serving the NHS to "take a lot of ground and take down a lot of political resistance." 
  • Also Read: 'Bad Times Are Incredibly Good For Palantir:' CEO Alex Karp
  • The suitable U.K. takeover targets were those with credible leadership, annual revenue of between £5 million and £50 million, and already selling software services to the NHS.
  • Since 2020, Palantir bagged over £37 million in contracts with the NHS and the Department of Health and Social Care, the report specified, citing public spending tracker AdviceCloud.
  • Key client NHS hired Palantir to help respond to COVID-19 and currently has a £360 million contract for tender.
  • Palantir hopes to deepen its business with a critical client by making key hires from the NHS and via potential acquisitions. 
  • Palantir has faced criticism in countries including the U.S. and U.K. for providing tools to government agencies that help enable broad surveillance of populations.
  • Palantir acknowledged winning NHS business on merit.
  • Recently Palantir won a $229 million deal to develop and deliver artificial intelligence and machine learning capabilities for the Special Forces, the Joint Staff, and every branch of the U.S. Armed Services
  • Price Action: PLTR shares traded higher by 0.87% at $8.15 in the premarket on the last check Friday.
Overview Rating:
Speculative
50%
Technicals Analysis
100
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!